Full Breakdown
WTA Mandates One-Time SRY Gene Test for All Female Players Starting July 2026
7/20/2026, 12:34:38 PM
Core Event
The Women’s Tennis Association (WTA) has adopted a new “Women’s Eligibility Policy” that requires every player on the women’s tour to undergo a one-time genetic screening for the SRY gene—the DNA segment that typically initiates male development. The test, performed via cheek swab or blood draw, will determine eligibility to compete in WTA tournaments. Screening is scheduled to begin on July 1, 2026, and players who refuse or are found ineligible face disciplinary action, including possible periods of ineligibility and public disclosure of the reason for exclusion.
Background & Context
Until 2024, the WTA allowed transgender women to compete if they declared a female gender identity and maintained serum testosterone below 2.5 nmol/L for at least 24 months, mirroring the International Olympic Committee’s hormone-suppression model. No transgender women have competed on the professional circuit since Renee Richards in the late 1970s. In recent years, several international federations—World Athletics, World Boxing, and the IOC—have shifted toward biological-sex definitions, prompting the WTA’s policy change.
Key Figures & Groups
- WTA spokesperson – provided the official explanation of the new screening.
- Aryna Sabalenka – world number one who previously said it would be unfair for women to face transgender players.
- Martina Navratilova – former champion and vocal critic of transgender inclusion in sport.
- Billie Jean King – former champion who views exclusion as discrimination.
- Professor Andrew Sinclair – discoverer of the SRY gene, who has publicly questioned its use as a sole eligibility marker.
- Transgender advocacy groups – label the policy discriminatory.
Data & Statistics
- The policy replaces the prior testosterone threshold of 2.5 nmol/L with a binary genetic marker (presence/absence of the SRY gene).
- The WTA reports zero known transgender women currently active at any professional level.
- Similar genetic-testing requirements have been adopted by World Athletics and World Boxing.
Why It Matters / Impact
The shift to a genetic definition of sex places the WTA at the forefront of a global debate over fairness versus inclusion. Proponents argue it safeguards a level playing field for biological females; opponents contend the test is invasive, reduces complex biology to a single gene, and may violate human-rights standards. The policy could set a precedent for other sports, influence legal challenges in international arbitration, and affect athletes with conditions such as Complete Androgen Insensitivity Syndrome (CAIS), who may receive case-by-case exemptions.
Official Statements & Responses
The WTA states that “Eligibility to participate in WTA tournaments will be confirmed through a required, one-time screening process for the SRY gene.” It emphasizes confidentiality, data-privacy safeguards, and a “comprehensive player engagement program.” The organization also pledges “professional counselling or such other support services” for players whose cases are assessed under the policy.
Criticism & Opposition
Trans-rights advocates describe the mandate as “discriminatory” and “invasive,” arguing that it ignores the nuanced interplay of dozens of genes involved in sexual development. Scientific critics, including Professor Sinclair, note that “sexual development involves dozens of interacting genes beyond SRY,” challenging the test’s validity as a sole determinant of athletic advantage.
Conflicting Reports & Gaps
- Policy inclusion: One source indicates the rule will be binding from July 2026, while another notes the new policy has not been incorporated into the updated 2026 WTA Rulebook.
- Governing law: The policy is said to be governed by Florida law, whereas the 2024 framework operated under New York law.
- No public data exist on how many players may test positive, leaving the practical impact uncertain.
Verbatim Quotes
- “Eligibility to participate in WTA tournaments will be confirmed through a required, one-time screening process for the SRY gene,” — WTA spokesperson
- “Player screening will begin in 2026, following all appropriate confidentiality and data privacy safeguards and concurrent with a comprehensive player engagement program.” — WTA spokesperson
- “1.1 The purpose of this policy is to preserve the integrity of women’s professional tennis and maintain fair competition conditions for all players participating in WTA Tournaments.” — WTA Rulebook, Section 1.1
What’s Next
The policy takes effect on July 1, 2026. The WTA has indicated that disciplinary measures will be enforced for non-compliance, and the organization anticipates legal scrutiny in international sports arbitration tribunals. Stakeholders will monitor how the rule influences eligibility standards across other federations and whether exemptions for conditions such as CAIS are granted.
